U.S. CBD Pouches Market Size, Share & Forecast 2026–2032

ID: MR-11289 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: CBD Pouches
  • ✓Market Size 2024: USD 285 million
  • ✓Market Size 2032: USD 611 million
  • ✓CAGR: 10.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Full-Spectrum Reformulation Pressure: The per-container THC cap of 0.4 milligrams under the November 2025 federal appropriations law reclassifies many full-spectrum pouches as intoxicating products from November 2026. Isolate-based producers carry lower compliance exposure, so share will shift toward them in convenience retail.
FINDING 02
FDA Pathway Assumption Fails: Most investors assume FDA approval will open grocery and pharmacy shelves, yet FDA has offered no lawful food or supplement pathway for CBD since its 2019 statement. Growth will come from hemp-licensed specialty retail and online direct-to-consumer channels instead.
ANALYST RECOMMENDATION

Analyst Recommendation — Reformulate Before Deadline: Brand owners should reformulate pouch SKUs to THC-free isolate profiles and secure third-party certificates of analysis before November 12, 2026, because the per-container THC limit takes effect that day and noncompliant SKUs face removal first.

CBD Pouches in the United States: Market Overview

The U.S. CBD pouches market comprises hemp-derived, nicotine-free oral pouches containing cannabidiol, sold through convenience retail, specialty hemp shops, and direct-to-consumer websites. The category was valued at an estimated USD 285 million in 2024, and its structure reflects federal hemp law far more than any dedicated product standard. Government set the supply base through the 2018 Farm Bill and USDA hemp rules, while private brands led product formulation, packaging, and retail distribution.

Policy created a legal gap rather than a licensed category. The Agriculture Improvement Act of 2018 (Public Law 115-334) removed hemp from the Controlled Substances Act, but the FDA stated in December 2018 that CBD cannot be added to food or sold as a dietary supplement. Pouches therefore compete as unregulated wellness goods, and private companies have filled the vacuum with third-party testing and voluntary certificates of analysis while federal regulators act mainly through warning letters.

Policy-Driven Growth in US CBD Pouches

The first mechanism is the 2018 Farm Bill hemp definition, which caps delta-9 THC at 0.3 percent on a dry-weight basis. That threshold enabled licensed cultivation under the USDA Agricultural Marketing Service Domestic Hemp Production Program, codified in 7 CFR Part 990 with a final rule in October 2021. Traceable feedstock lowers input costs and gives pouch formulators the supply consistency needed for scaled national distribution.

The second mechanism is state-level licensing, administered by agencies such as the Kentucky Department of Agriculture, which issues hemp processor licences that document chain of custody from field to finished product. The third mechanism is the FDA's January 2025 authorisation of ZYN nicotine pouches under the Family Smoking Prevention and Tobacco Control Act. That authorisation normalised oral pouches on mainstream shelves, and adult consumers who switch to nicotine-free pouches keep the same format and purchase routine.

Regulatory Barriers and Compliance Costs

The FDA administers the Federal Food, Drug, and Cosmetic Act, under which adding CBD to food renders a product adulterated and misbranded. Because no premarket approval pathway exists for CBD in foods or supplements, brands bear ongoing costs for outside counsel, label review, and warning-letter response. The FTC enforces Section 5 of the FTC Act, requiring competent and reliable scientific substantiation for any health claim on pouch packaging or digital advertising.

USDA AMS requires batch-level THC testing to confirm compliance with the 0.3 percent limit, and brands typically use ISO/IEC 17025 accredited laboratories at an estimated USD 250 to USD 600 per batch. State hemp licensing adds registration fees, annual renewals, and facility inspections that vary by jurisdiction. Reformulating products to meet the November 2026 per-container THC limit adds further reformulation and relabelling costs for brands with full-spectrum portfolios.

Policy-Created Opportunities in the United States

The November 2026 per-container THC cap creates demand for compliance-certified isolate pouch lines. Producers holding USDA AMS-compliant feedstock and documented THC-free formulations can capture shelf space vacated by full-spectrum competitors in convenience retail. Early reformulation gives isolate brands a measurable head start before enforcement begins.

Testing and certification represent a second opportunity. Accredited laboratories that deliver ISO/IEC 17025 batch reports aligned with USDA AMS documentation will serve every licensed brand that must prove compliance. Contract manufacturers already operating FDA-compliant nicotine pouch filling lines can diversify into hemp-derived pouches, using existing automation and quality systems to enter the category quickly.

Market at a Glance

MetricValue
Market Size 2024USD 285 million
Market Size 2032USD 611 million
Growth Rate (CAGR)10.0%
Most Critical Decision FactorFederal THC per-container compliance under 2026 appropriations law
Largest RegionSouth
Competitive StructureFragmented, with top ten brands holding under 40% share

Leading Market Participants

  • Charlotte's Web
  • cbdMD
  • Lord Jones
  • Hemp Bombs
  • Elixinol
  • Cornbread Hemp
  • Panacea Life Sciences
  • Bluebird Botanicals
  • Kanha
  • Pure Kana

Regulatory and Policy Environment

The primary legislation is the Agriculture Improvement Act of 2018 (Public Law 115-334), supplemented by the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37). The appropriations act, enacted in November 2025, redefines hemp to exclude products exceeding 0.4 milligrams of total THC per container, effective November 12, 2026. The FDA enforces labelling and food safety under the Federal Food, Drug, and Cosmetic Act, USDA AMS governs hemp production under 7 CFR Part 990, and the FTC polices advertising claims under Section 5 of the FTC Act.

Compared with regional peers, the U.S. framework permits sale without a federal authorisation pathway, which is more permissive than the EU Novel Food Regulation (EU) 2015/2283, under which CBD foods require pre-market authorisation. Canada's Cannabis Act (S.C. 2018, c. 16) subjects cannabis products, including edibles, to Health Canada licensing and quality controls. Congressional bills to create a federal CBD pathway have been introduced but not enacted, leaving U.S. consumer protection weaker than both peers.

Long-Term Policy Outlook for CBD Pouches in the US

The November 2026 THC cap will reshape the category by pushing full-spectrum pouch formats toward discontinuation and concentrating share among THC-free isolate producers. Congress has extended the 2018 Farm Bill repeatedly since its five-year term ended in 2023, and pending reauthorisation will determine whether the hemp definition and USDA AMS framework remain intact. Brands that build compliant supply chains now will be positioned for that reauthorisation outcome.

By 2032, the market is projected to reach USD 611 million at a 10.0% CAGR, with growth concentrated in states that maintain clear licensing rules. State-level restrictions will continue to fragment distribution, favouring brands that document compliance in every jurisdiction. Expect federal pressure on health claims to rise through FTC enforcement, making substantiated labelling a prerequisite for market access.

Frequently Asked Questions

Hemp-derived products containing no more than 0.3 percent delta-9 THC on a dry-weight basis are legal under the Agriculture Improvement Act of 2018. The FDA maintains that CBD cannot be added to food or sold as a dietary supplement.
The November 2025 appropriations act caps total THC at 0.4 milligrams per container, effective November 12, 2026. Products exceeding that cap will be classed as intoxicating hemp products.
USDA AMS governs hemp production and THC testing under 7 CFR Part 990. The FDA oversees finished pouch labelling and safety under the Federal Food, Drug, and Cosmetic Act.
No federal premarket approval pathway currently exists for CBD in food or dietary supplements. The FDA enforces compliance through warning letters and labelling standards.
The FTC requires health claims to be substantiated under Section 5 of the FTC Act. Retailers and platforms also enforce age-gating and state-level restrictions on hemp product sales.

Market Segmentation

By Product Type
  • CBD Isolate Pouches
  • Full-Spectrum Pouches
  • Broad-Spectrum Pouches
  • CBD with Botanical Extracts
By Distribution Channel
  • Convenience Stores
  • Vape and Smoke Shops
  • Specialty Hemp Retailers
  • Online Direct-to-Consumer
  • Mass Merchandisers
By End User
  • Adults Aged 25–44
  • Adults Aged 45–64
  • Wellness Consumers
  • Former Nicotine Pouch Users
  • Chronic Pain Sufferers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. CBD Pouches - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 CBD Isolate Pouches
4.2 Full-Spectrum Pouches
4.3 Broad-Spectrum Pouches
4.4 CBD with Botanical Extracts
4.5 Others
Chapter 05 Distribution Channel Insights
5.1 Convenience Stores
5.2 Vape and Smoke Shops
5.3 Specialty Hemp Retailers
5.4 Online Direct-to-Consumer
5.5 Others
Chapter 06 End User Insights
6.1 Adults Aged 25–44
6.2 Adults Aged 45–64
6.3 Wellness Consumers
6.4 Former Nicotine Pouch Users
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Charlotte's Web
7.2.2 cbdMD
7.2.3 Lord Jones
7.2.4 Hemp Bombs
7.2.5 Elixinol
7.2.6 Cornbread Hemp
7.2.7 Panacea Life Sciences
7.2.8 Bluebird Botanicals
7.2.9 Kanha
7.2.10 Pure Kana
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.